Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0630

-1.6%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: NTTG	5/1/2012 8:29:54 AM
	5 Recommendations Read Replies (1) of 13111

Altor has secured funding for a PI study of a novel IL15 superagonist from the Melanoma Research Alliance, in addition to funding from the Small Business Innovation Grants from NCI. The alliance supports research on promising novel therapeutics. Nice company; they have 5 PII trials running in cancer and life threatening autoimmune disease, solid names on their clinical/scientific advisory boars. Why can't PVCT get funding from sources like these...or the NIH...or NSF..or big pharma? Shame they are not publicly traded, look at those publications...wonder what their management team gets paid per year, bonuses and all, for this level of productivity? altorbioscience.com sbir.cancer.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next